{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"INDUCE-1","nct_id":"NCT02723955","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=induce-1-nct02723955. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.","label":"Part 1A: Dose escalation feladilimab (GSK3359609)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.","label":"Part 1B: Expansion feladilimab (GSK3359609)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.","label":"Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.","label":"Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)","type":"EXPERIMENTAL"},{"description":"Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.","label":"Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.","label":"Part 2B: Expansion-feladilimab (GSK3359609)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.","label":"Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.","label":"Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)","type":"EXPERIMENTAL"},{"description":"Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.","label":"Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2023-07-05","type":"ACTUAL"},"conditions":["Neoplasms"],"enrollment":{"count":829,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"feladilimab (GSK3359609)","otherNames":[],"type":"DRUG"},{"name":"GSK3174998","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel plus Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine plus Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Fluorouracil (5-FU) plus carboplatin or cisplatin","otherNames":[],"type":"DRUG"},{"name":"Dostarlimab","otherNames":[],"type":"DRUG"},{"name":"Cobolimab","otherNames":[],"type":"DRUG"},{"name":"Bintrafusp alfa","otherNames":[],"type":"DRUG"}],"last_update":"2024-12-27","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-07-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)","timeFrame":"Up to 28 days"},{"measure":"Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters","timeFrame":"Baseline (Day 1) and up to approximately 367 weeks"},{"measure":"Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters","timeFrame":"Baseline (Day 1) and up to approximately 367 weeks"},{"measure":"Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 1A: Number of Participants With Dose Modifications of Feladilimab","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)","timeFrame":"Up to 28 days"},{"measure":"Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters","timeFrame":"Baseline (Day 1) and up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters","timeFrame":"Baseline (Day 1) and up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline","timeFrame":"Up to approximately 367 weeks"},{"measure":"Part 2A: Number of Participants With Dose Modifications of Feladilimab","timeFrame":"Up to approximately 367 weeks"}],"references":[{"citation":"Turner DC, Wada R, Zhou H, Wang X, de Greef R, Valiathan C, Zhang L, Zhang N, Kuchimanchi M, Chen TT, Ballas M, Visser SAG. Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1751-1763. doi: 10.1002/psp4.12917. Epub 2023 Jan 31.","pmid":"36642813","type":"BACKGROUND"},{"citation":"Yadavilli S, Waight JD, Brett S, Bi M, Zhang T, Liu YB, Ellis C, Turner DC, Hahn A, Shi H, Seestaller-Wehr L, Jing J, Xie Q, Shaik JS, Ji X, Gagnon R, Fieles W, Hook L, Grant S, Hopley S, DeYoung MP, Blackwell C, Chisamore M, Biddlecombe R, Figueroa DJ, Hopson CB, Srinivasan R, Smothers J, Maio M, Rischin D, Olive D, Paul E, Mayes PA, Hoos A, Ballas M. Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer Res Commun. 2023 Aug 16;3(8):1564-1579. doi: 10.1158/2767-9764.CRC-22-0293. eCollection 2023 Aug.","pmid":"37593752","type":"DERIVED"}],"start_date":{"date":"2016-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","url":"https://clinicaltrials.gov/study/NCT02723955"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/induce-1-nct02723955"}